Gilead Sciences Inc. (GILD) Nasdaq Global Select
64.84-0.28-0.43%
CloseDecember 18, 2018

News: updated – 19-Dec 04:47


The New Generex: Unlocking The Value18-Dec 12:50(SeekingAlpha)

The principal research of Generex Biotechnology ( GNBT ) for years has been its buccal delivery system. The buccal tissue is the tissue on the inside of the cheek and under the tongue. Generex buccal delivery sprays a solution under a high gas aerosol formulation containing a drug on to the bl…

Liver Therapy Forum: A Specialized Marketplace Service For Liver Therapeutics Investment Opportunities18-Dec 09:30(SeekingAlpha)

Editors’ Note: This article is meant to introduce First Genesis Consulting’s Marketplace service, Liver Therapy Forum . Why Liver Therapeutics Investing? There is significant public interest in chronic liver diseases such as NASH and Cholestatic liver diseases in the last 5-10 years …

Credit Suisse sees 18% upside in Abbott in premarket analyst action18-Dec 08:05(SeekingAlpha)

Abbott (NYSE: ABT ) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse. More news on: Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Baxter International Inc, Healthcare stocks news, Stocks on the move, , Read more …

The First Ever Alphies (Podcast)18-Dec 06:30(SeekingAlpha)

by Daniel Shvartsman It’s rough out there, or so Jeffrey Gundlach says . After the anodyne rise of 2017, the last quarter of 2018 has been genuinely startling. Whether the king of bonds is right that this marks a true turning point into a bear market or it’s just a bit of a jostling befor…